Home » Stocks » Atreca

Atreca, Inc. (BCEL)

Stock Price: $14.91 USD -3.51 (-19.06%)
Updated Jul 16, 2020 1:20 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 419.49M
Revenue (ttm) n/a
Net Income (ttm) -74.32M
Shares Out 22.27M
EPS (ttm) -6.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 16, 2020
Last Price $14.91
Previous Close $18.42
Change ($) -3.51
Change (%) -19.06%
Day's Open 15.31
Day's Range 14.58 - 15.59
Day's Volume 1,790,465
52-Week Range 9.51 - 29.35

More Stats

Market Cap 419.49M
Enterprise Value 268.47M
Earnings Date (est) Aug 18, 2020
Ex-Dividend Date n/a
Shares Outstanding 22.27M
Float 15.55M
EPS (basic) -5.2
EPS (diluted) -6.36
FCF / Share -2.40
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.25M
Short Ratio 9.48
Short % of Float 15.80%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.42
Revenue n/a
Operating Income -79.67M
Net Income -74.32M
Free Cash Flow -67.28M
Net Cash 151.02M
Net Cash / Share 5.37
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -34.57%
ROE -54.16%
ROIC -139.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 8
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(103.76% upside)
Current: 14.91
Target: 30.38
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-72.57-39.57-29.44
Net Income-67.48-37.94-27.53
Shares Outstanding15.832.1012.57
Earnings Per Share-4.26-18.02-2.19
Operating Cash Flow-58.54-34.70-25.10
Capital Expenditures-3.45-1.76-1.38
Free Cash Flow-61.99-36.46-26.47
Cash & Equivalents17311530.61
Total Debt0.050.100.20
Net Cash / Debt17311430.42
Book Value187-93.03-56.57
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Atreca, Inc.
Country United States
Employees 118
CEO John A. Orwin

Stock Information

Ticker Symbol BCEL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BCEL


Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in clinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a strategic research collaboration with Merck Sharp & Dohme Corp. to identify the antigenic targets of select antibodies discovered with potential utility in oncology. Atreca, Inc. was founded in 2010 and is headquartered in South San Francisco, California.